RYE, N.Y., April 26 Curemark, LLC, (www.curemark.com), a drug research and development company focused on the treatment of neurological diseases, announced that the company is now enrolling Phase III clinical trials for CM-AT, its autism treatment, at the UC Davis MIND Institute (Medical Investigation of Neurodevelopmental Disorders).
Advertisement
UC Davis MIND Institute joins Curemark's network of more than 12 sites across the country conducting CM-AT trials with a total 170 children. The MIND Institute is an internationally renowned research center for understanding autism and other neurodevelopmental disorders. With a staff of over 250, the center brings together experts in neuroscience, education, immunology, genetics, molecular biology, psychology and developmental pediatrics.
Advertisement
"We are very pleased to be working with the MIND Institute, one of the premier research institutions in the world for autism and other neurological disorders," said Dr. Joan Fallon, Curemark founder and CEO. "The MIND Institute is renowned as a leader for its state-of-the-art research and interdisciplinary approach to finding innovative new ways to treat neurodevelopmental conditions."
Curemark's CM-AT is based on Dr. Fallon's research that showed enzyme deficiencies in autistic children, resulting in an inability to digest protein. The inability to digest protein affects the production of amino acids, the building blocks of chemicals essential for brain function. CM-AT, which recently was designated by the FDA as a Fast Track drug, will be one of the first therapies to address the underlying physiology of autism, rather than just treat its symptoms.
For information on participating in the Curemark CM-AT autism trials, log on to www.clinicaltrials.gov and search "Curemark."
About CUREMARK LLC
Curemark is a drug research and development company focused on the treatment of neurological and other diseases, especially those with dysautonomic components, by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company's initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon, which revealed a lack of protein digestion in children with autism and ADHD. To learn more about our innovative science, visit www.curemark.com
Safe Harbor Statement
This news release contains forward-looking statements that involve risks and uncertainties that could cause our actual results and experiences to differ materially from anticipated results and expectations expressed in such forward-looking statement. These forward-looking statements include, without limitation, statements regarding the mechanism of action of CM-AT, its potential advantages, its potential for use in treating autism, as well as the timing, progress and anticipated results of the clinical development and regulatory processes concerning CM-AT. These statements are based on our current beliefs and expectations as to such future outcomes, and are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. Factors that might cause such a material difference include, among others, risks that the results of clinical trials will not support our claims or beliefs concerning the effectiveness of CM-AT, our ability to finance our development of CM-AT, regulatory risks, and our reliance on third party researchers and other collaborators. We assume no obligation to update these statements, except as required by law.
SOURCE Curemark, LLC
